ArticleSouthern med review2012
Impact of external price referencing on medicine prices - a price comparison among 14 European countries.
Article in Southern med review, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Does external reference pricing deliver what it promises? Evidence on its impact at national level.The European journal of health economics : HEPAC : health economics in prevention and care · 2020Pooled it
- Variations in external reference pricing implementation: does it matter for public policy?The European journal of health economics : HEPAC : health economics in prevention and care · 2019Pooled it
- International impact of external reference pricing: should national policy-makers care?The European journal of health economics : HEPAC : health economics in prevention and care · 2019Pooled it
- The impact of the United States most favored nation policies on prices of branded medicines and research and development.Health policy OPEN · 2026Review
- The impact of annual price revision based on external reference pricing on medicines between 2012 and 2023.Health economics review · 2026Article
- Assessment of IPAY 2027 Medicare drug price negotiation maximum fair prices with prices in most-favored nation reference countries.Journal of managed care & specialty pharmacy · 2026Article
- How does external reference pricing work in developing countries: evidence from Iran.Frontiers in pharmacology · 2023Article
- International reference pricing of pharmaceuticals in the United States: Implications for potentially curative treatments.Journal of managed care & specialty pharmacy · 2022Article
- Impact of changes in the methodology of external price referencing on medicine prices: discrete-event simulation.Cost effectiveness and resource allocation : C/E · 2020Article
- Integrative Review of Managed Entry Agreements: Chances and Limitations.PharmacoEconomics · 2020Review
- Price-Cutting Trends in New Drugs after Listing in South Korea: The Effect of the Reimbursement Review Pathway on Price Reduction.Healthcare (Basel, Switzerland) · 2020Article
- Does price regulation affect atorvastatin sales in India? An impact assessment through interrupted time series analysis.BMJ open · 2019Article
- Higher pharmaceutical public expenditure after direct price control: improved access or induced demand? The Colombian case.Cost effectiveness and resource allocation : C/E · 2018Article
- Article
- Affordability of medicines in the European Union.PloS one · 2017Article
- Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology Drugs.Frontiers in pharmacology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aims to examine the impact of external price referencing (EPR) on on-patent medicine prices, adjusting for other factors that may affect price levels such as sales volume, exchange rates, gross domestic product (GDP) per capita, total pharmaceutical expenditure (TPE), and size of the pharmaceutical industry.
methodsPrice data of 14 on-patent products, in 14 European countries in 2007 and 2008 were obtained from the Pharmaceutical Price Information Service of the Austrian Health Institute. Based on the unit ex-factory prices in EURO, scaled ranks per country and per product were calculated. For the regression analysis the scaled ranks per country and product were weighted; each country had the same sum of weights but within a country the weights were proportional to its sales volume in the year (data obtained from IMS Health). Taking the scaled ranks, several statistical analyses were performed by using the program "R", including a multiple regression analysis (including variables such as GDP per capita and national industry size).
resultsThis study showed that on average EPR as a pricing policy leads to lower prices. However, the large variation in price levels among countries using EPR confirmed that the price level is not only driven by EPR. The unadjusted linear regression model confirms that applying EPR in a country is associated with a lower scaled weighted rank (p=0.002). This interaction persisted after inclusion of total pharmaceutical expenditure per capita and GDP per capita in the final model.
conclusionsThe study showed that for patented products, prices are in general lower in case the country applied EPR. Nevertheless substantial price differences among countries that apply EPR could be identified. Possible explanations could be found through a correlation between pharmaceutical industry and the scaled price ranks. In conclusion, we found that implementing external reference pricing could lead to lower prices.
Indexed as
Identifiers
23532710PMC3606937What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.